NovaBridge Biosciences News and Activities

NovaBridge Biosciences is a company listed under the stock ticker IMAB (CN).

Acquisition, funding and merger involving NovaBridge Biosciences.

• The new name of I-Mab Biopharma is NovaBridge Biosciences. (posted on October 20 2025).
• I-Mab Biopharma will change its company name to NovaBridge Biosciences. (posted on October 17 2025).

View the org chart displaying its 22 main executives

Most searched biographies at NovaBridge Biosciences

• Srishti Gupta, Chief Executive Officer
• Wei Fu, Executive Chairman of the Board
• Robert Lenz, Independent Director

Popular executive movements at NovaBridge Biosciences

• Kevin Li has joined the company as Vice President Clinical Operations  (posted on June 29 2026).
• Srishti Gupta will join the company as Chief Executive Officer on Jul. 1, 2026  (posted on June 29 2026).
• Sean Fu, Chief Executive Officer, has left the company  (posted on June 29 2026).

Click here to view some more movements at NovaBridge Biosciences

Create your alert
to follow the executive moves at NovaBridge Biosciences.

NovaBridge Biosciences has 1,918 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).
• Novartis has announced the acquisition of Myricx Bio  (posted on July 6 2026).
• Ipsen has announced the acquisition of Kartos Therapeutics  (posted on July 3 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna

Learn more about the Pharmaceuticals industry

Press releases by NovaBridge Biosciences

• NovaBridge Biosciences | NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
• NovaBridge Biosciences | NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
• NovaBridge Biosciences | NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
• NovaBridge Biosciences | News
• NovaBridge Biosciences | NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
• NovaBridge Biosciences | News
• I-Mab | I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
• I-Mab | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
• I-Mab | News Releases
• I-Mab | I-Mab to Host 2022 R&D Day
• View more press releases Close

Social media about NovaBridge Biosciences

• NovaBridge Biosciences on Wikipedia, Google News & Yahoo Finance
• NovaBridge Biosciences on LinkedIn, X (Twitter) & YouTube